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Background: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary
disease (COPD) are two diseases that often coexist within an individual. This coexistence is
known as Overlap Syndrome (OS). Both diseases are characterized by local and systemic
inflammations, but no studies to date have investigated local airway inflammation in patients
suffering from Overlap Syndrome.
Methods: We performed a Berlin Questionnaire to evaluate the presence of the principal
OSAS symptoms, a pulmonary function test, and then a nocturnal oximetry and polysomno-
graphy in 72 patients that were divided into five groups: OS (n Z 18), COPD (n Z 15), OSAS
(n Z 16), 12 obese without OSAS or COPD, and one control group of 11 normal subjects. All
patients underwent sputum induction and the analysis of cell patterns were evaluated in all
groups. The relationship with the degree of obesity, airway obstruction and OSAS severity was
also evaluated.
Results: The percentage of neutrophils in induced sputum was higher in OS (74.33%  14.8),
COPD (63.33%  13.22) and OSAS (60.69%  17.6) subjects compared with control groups of
obese (43.5%  17.49) and normal weight (32.04%  12.26). No difference was found among
Overlap, COPD, and OSAS patients (p Z 0.56). A negative correlation was found between
PaO2 and percentage of airway neutrophils (r Z 0.29, p < 0.05); similarly, no correlations
arose between BMI, FEV1 or ODI.tive pulmonary disease; OSAS, obstructive sleep apnea syndrome; OS, Overlap Syndrome; IS, induced
index; ODI, oxygen desaturation index; BMI, body mass index; TST90, total sleep time with SaO2
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304 D. Lacedonia et al.Conclusion: Patients suffering from Overlap Syndrome present a high percentage of neutro-
phils in induced sputum like patients affected by COPD or OSAS alone. Our result suggests
that airway inflammations is always involved in all of these diseases, even though probably
sustained by different mechanisms.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a frequent
pulmonary pathology whose prevalence has been estimated
to be 1% of the general population and up to 5e10% of the
older adult population; it is a condition of progressive
deterioration of the respiratory system characterized by an
obstruction of the pulmonary airways and decreasing
expiratory airflow. COPD is defined by the presence of an
obstructive ventilatory defect, characterized by a FEV1/
FVC ratio less than 70%1 and it is associated with an
abnormal inflammatory response of the lungs to noxious
particles or gases, primarily caused by cigarette smoking.2
Obstructive sleep apnea syndrome (OSAS), a highly
prevalent disorder affecting approximately 4% of the adult
population,3 is characterized by recurrent upper airway
collapse and episodes of hypoxia/reoxygenation during
sleep.4
OSAS sometimes coexists with COPD and so it creates
a disease with particular characteristics commonly known
as “Overlap Syndrome.”(OS).5 OS can be expected to be
present in 0.5e1% of the population over 40 years of age.6
The prevalence of OSAS is the same in subjects with COPD
as those without COPD, the association between COPD and
OSAS occurring by chance. OS predisposes to daytime
hypercapnia and hypoxemia independently of lung func-
tion.7 Nocturnal arterial oxyhemoglobin desaturation and
diurnal hypoxemia and hypercapnia are more pronounced
in patients with coexistent COPD and OSA than in patients
with either condition. Patients with both conditions have
a greater risk of pulmonary hypertension and heart failure
compared to patients with COPD or OSA alone.8,9
Both diseases are characterized by local and systemic
inflammations. Several studies found an increase of local
biomarkers of inflammations in OSAS: Rubinstein10 showed
an increase in the percentage of PMN (Polymorphonuclear
leukocyte) in the nasal mucosa of patients suffering from
OSAS, while our group found an increase of the neutrophilic
percentage in induced sputum.11
On the other hand, in COPD also, much of the evidence
demonstrates that airway inflammation is central to the
pathogenesis of both airway remodelling and parenchymal
destruction.12 The cellular inflammatory response is char-
acterized by an increase in neutrophils, and CD8-positive T-
lymphocytes in small and large airways as well as in lung
parenchyma.13
However, as far as we know, no studies to date have
investigated airway inflammation characteristics in
patients with both diseases. We investigated the hypothesis
according to which the presence of OSAS and COPD can
increase local inflammation and pulmonary damage.
In order to test this hypothesis, we investigated the
bronchial inflammatory cell profile in OSAS, COPD and OSpatients by using the analysis of the induced sputum
which e even if it does not cover all the inflammatory and
structural changes of the lungs e it can be useful in eval-
uating the cell airway composition in pulmonary disease.Material and methods
Subjects
160 subjects afferent to Sleep Laboratories of the Institute
of Respiratory Diseases, University of Foggia and Fonda-
zione Maugeri, Cassano Murge (Bari) with suspected OSAS
were initially screened. 88 subjects respected inclusion
criteria (no history of systemic diseases, no current smokers
or ex-smokers for at least 2 years, FEV1 >30% of predicted,
free from inhaled steroids or other anti-inflammatory drugs
for at least 6 months, no COPD exacerbations in the
previous year), 7 subjects refused their consent to
the study; furthermore, 20 patients were excluded because
the quality of induced sputum was not suitable for analysis,
with the result that 61 subjects completed the study.
Indeed, 11 lean, healthy volunteers were also enrolled for
control group purposes.
None of the subjects was using CPAP therapy at that
time. The Berlin Questionnaire14 used for screening the
presence of OSAS symptoms, a pulmonary function test,
a nocturnal oximetry and induced sputum test were per-
formed in all subjects. All healthy and COPD subjects who
presented no risk of OSAS at the Berlin Questionnaire and
no alterations of nocturnal oximetry, did not undergo
a polysomnography. Subjects with a high risk of OSAS in the
Berlin questionnaire, ODI >10 or BMI>25 kg/m2, never-
theless performed a full polysomnography. All subjects
written informed consent, and the study was approved by
the institutional ethics committee. A complete physical
examination was performed, including neurological,
cardiopulmonary, ear, nose and throat examinations.
According to the result of the pulmonary functions test
and polysomnography data, we divided the patients into 5
groups: group 1 (COPD/OSAS þ/þ) 18 subjects, group 2
(COPD/OSAS þ/) 15 subjects, group 3 (COPD/OSAS /þ)
16 subjects, group 4 (Obese COPD/OSAS /) 12 subjects
and group 5 (lean COPD/OSAS /) 11 subjects.
Nocturnal oximetry
Nocturnal haemoglobin oxygen saturation was evaluated by
finger pulse oximetry (Minolta, Pulsox DP 8, Japan). A
pattern of oximetry tracing positive for OSAS was defined as
a cyclical oxygen desaturation and a drop in oxygen satu-
ration >4%. The test was considered valid if at least 6 h
recording were analyzable.
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Pulmonary function tests (Vmax 6200 Autobox, Sensor-
Medics, Yorba Linda, CA) were performed before starting
the study, in order to exclude an obstructive lung disease
defined as a FEV1 % predicted less than 80 and a FEV1/FVC
ratio less than 0.7.
Polysomnography
Overnight full polysomnography was performed in the sleep
laboratory (Sleep Lab 1000p, Aequitron Medical, MN, USA).
Sleep-disordered breathing was quantified by RDI (respira-
tory disturbance index), the average number of respiratory
events (apneas þ hypopneas) per hour of sleep. This was
calculated by dividing the total number of respiratory
events during the study by the number of hours of sleep.
Sleep-disordered breathing was quantified according to
standard criteria.15
Induced sputum technique
Inhalation procedure: after baseline FEV1 and FVC
measurements, salbutamol was given to subjects by inha-
lation (200 mg by MDI, metered-dose inhaler) and subjects
inhaled hypertonic (4.5%) saline nebulized for three periods
of 5 min each. An ultrasonic nebulizer (De Vilbiss 65, De
Vilbiss Corporation, Somerset, PA, USA), nebulized saline
solutions.
Sputum processing: the collected sputum samples were
examined within 2 h. Selected portions of the sputum
sample originating from the lower respiratory tract were
analyzed. Dithiothreitol (DTT, Sputolysin, Calbiochem Corp,
San Diego, CA, USA), freshly prepared in a dilution of one in
10 with distilled water, was added to a volume equal to 4
times the weight of the sputum portion. Selected sputum
was placed in a shaking water-bath at 37 C for 20 min and
homogenized. It was further diluted with phosphate-buff-
ered saline in a volume equal to the sputum plus DTT. The
suspension was filtered through gauze to remove any mucus
and was centrifuged at 1000 rpm for 5 min. The cell pellet
was resuspended in a volume of PBS equal to that of the
sputum plus DTT and PBS, as above. Total cell count (TCC)
and viability (Trypan blue exclusion method) were deter-
mined using a Burkers chamber haemocytometer. The cell
suspension was placed in a Shandon 3 cytocentrifuge
(Shandon Southern Instruments, Sewickley, PA, USA) and
cytospins were prepared at 450 rpm for 6 min. Cytospin
slides were fixed by methanol and stained by May Grunwald
Giemsa for an overall differential cell count on 500 nucle-
ated non-squamous cells. Only samples with cell viability
>50% and squamous cell contamination <20% were
considered adequate. The slides were read by two inde-
pendent investigators.
Statistical analysis
Differences among five groups (Overlap, COPD, OSAS,
Obese, normal) were tested by the ANOVA for normally
distributed variables and the KruskaleWallis test for non-
normally distributed variables. Post hoc analyses byBonferroni correction were performed. Correlations
between functional and biological parameters, and
inflammatory cells were evaluated by means of Spear-
man’s rank correlation test. Significance was defined as
a p value less than 0.05. Data are presented as mean-
 Standard Deviation.
Results
There were no significant differences in BMI between
Overlap, OSAS and Obese patients (p Z 0.29); however, it
was significant among all groups (p < 0.001). This was
related to a lower BMI in COPD and the control lean group.
Although there was no RDI difference among Overlap and
OSAS patients (pZ 0.17), by design, there was a difference
with control group (p < 0.001). There was no difference in
pulmonary function between overlap and COPD; Table 1
shows the characteristics of the five groups.
The percentage of neutrophils (Fig. 1) in induced sputum
was higher in Overlap, COPD and OSAS group, compared
with obese and lean subjects without OSAS or COPD. No
significant difference was found among the three groups of
patients: overlap vs group COPD (74.33  14.8 vs
63.33  13.22, pZ 0.37); overlap vs OSAS (74.33  14.8 vs
60.69  17.6, p Z 0.15); and between COPD and OSAS
(63.33  13.22 vs 60.69  17.6, pZ 0.99). The percentage
of macrophage cells was lower in Overlap, COPD and in
OSAS patients than control groups (p < 0.05). There was no
significant difference among these three groups. In Overlap
patients the percentage of lymphocytes (0.06  0.24) was
lower than all other groups (p < 0.01). Finally, the eosin-
ophils were higher in COPD than the other groups
(p < 0.05).
Concerning gas exchange, no significant difference was
shown in PaCO2 and PaO2 values among three groups of
patients. There was no difference in TST90 between over-
lap and OSAS group (p Z 0.39).
A negative correlation was found between diurnal PaO2
and percentage of neutrophils in airway (r Z 0.29,
p < 0.05), no correlations were forthcoming with BMI
(rZ 0.07; pZ 0.61), FEV1(rZ 0.21; pZ 0.16) RDI or ODI
(r Z 0.01; p Z 0.93) and PaCO2 (Fig. 2) and with TST90
(r Z 0.24; p Z 0.16).
Discussion
The aim of this study was to evaluate airway inflammation
in Overlap Syndrome and establish if there were some
differences with respect to OSAS and COPD. Our data
demonstrates that patients suffering from Overlap
Syndrome show a higher percentage of neutrophils in their
airway than lean and obese subjects without COPD or OSAS,
but no difference with patients suffering from COPD or
OSAS alone. We can hypothesize that different mechanisms
are at the basis of the increased airway inflammations in
COPD and OSAS, so that when they are both present, like in
the Overlap Syndrome, each of them contributes to the
development of a pulmonary inflammation.
The first data that rose from this study is the increase of
eosinophils percentage in the induced sputum of COPD
patients. These results were also observed in patients with
Table 1 Characteristics of groups and airway cells compositions in each of them.
n Overlap (1) COPD (2) OSAS (3) Obese no (4) Lean no (5) p
18 15 16 12 11
Age (year) 64.93  10.25a 66.13  11.94a 58.5  7.16a 46.42  9.96 49.55  7.92 <0.01
BMI (kg/m2) 35.29  6.56b 30.58  3.9b 38.62  9.4b 34.29  7.17 20.41  2.12 <0.01
RDI (events/h) 38.85  17.28a 43.42  26.42a 5.35  2.78 <0.001
ODI (events/h) 38.89  16.11a 3.13  2.26 43.56  27.13a 3.51  3.16 0.64  0.81 <0.001
TST90 (%) 49.42  36.29a 1.1  1.28 36.38  27.4a 0.92  1.08 0 <0.001
FEV1 (%) 56  14.28a 59.69  14.01a 94.31  13.56 92.75  18.13 111.09  18.34 <0.001
FVC (%) 80.47  11.9a 74.92  16.18a 94.44  13.86 93.25  19.03 113  18.65 <0.001
FEV1/FVC 0.53  0.1a 0.62  0.07a 0.79  0.06 0.87  0.12 0.90  0.09 <0.001
PaO2 (mmHg) 65.36  7.99a 73.64  14.92a 72.09  9.83a 86.23  13.19 <0.01
PaCO2 (mmHg) 44.87  5.82 40.65  6.67 43.39  4.95 40.48  3.21 0.09
Macrophages (%) 23.94  13.63a 27.6  15.38a 35.31  15.8a 54.42  18.7 64.91  12.77 <0.01
Neutrophils (%) 74.33  14.8a 63.33  13.22a 60.69  17.06a 43.5  17.49 32.04  12.26 <0.01
Eosinophils (%) 1.28  1.96 6.07  8.18 0.59  0.95 1.33  1.56 0.09  0.21 <0.001
Lymphocytes (%) 0.06  0.24 4.89  3.02 2.03  3.21 0.67  1.04 1.04  1.27 <0.01
NO: Non OSAS. Data are expressed as mean  SD.
a Significant difference vs normal weight and/or obese.
b Significant difference vs normal weight but not vs obese.
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controversial.24 It has been argued that sputum eosinophilia
is related to concomitant features of asthma.25 This link
would indicate that the pathophysiologic entities under-
lying the clinical phenotypes in COPD may be diverse and
are still largely unknown.
The reductions of lymphocytes in OS are probably only
a consequence of an increase in the percentage of
neutrophils.
What is perhaps more interesting is our observation that
in Overlap Syndrome there is a high percentage of neutro-
phils in IS, and this increase of neutrophils is the same as we
found in COPD ad OSAS patients.
Neutrophils are front-line defensive cells of the immune
system and a source of reactive oxygen metabolites,
inflammatory cytokines, lipid mediators, antibacterial
peptides, and tissue-damaging enzymes.16 The in-vivo
evidence linking neutrophils with COPD is abundant.Figure 1 Percentage of neutrophils in the five groups: higher
in OS, COPD and OSAS than in control groups, any difference
inside three groups of patients.Analyses of induced sputum17,18 and airway lavage fluid19
consistently demonstrate increased neutrophil counts and
neutrophil-derived enzyme levels in COPD both when stable
and during exacerbations. Analyses of the airway smooth
muscle has shown a relationship between neutrophil infil-
tration, computed tomographic20 measurements of air
trapping and severity of airflow obstruction.21 The investi-
gators speculate that exposure to inflammatory mediators
could affect the structure and contractility of the airway
smooth muscle, contributing to peripheral airways
obstruction.
Several reasons can explain the migration of neutro-
phils from general circulation to parenchyma lung in
COPD. Firstly we know that in COPD patients, the inten-
sity of the airway and blood neutrophilia, in both smokers
and ex-smokers, correlates to the rate of decline in FEV1,
with the result that the severity of airflow limitation is
related to airway inflammation.26,27 So, the airways
dysfunction is a key determinant of COPD severity and
airway lumen neutrophilia is associated with this
dysfunction.18
Furthermore, there is the increase of chemotactic
protein in airways, in particular LTB4 and IL-8, which plays
a fundamental role in co-ordinating and facilitating
neutrophil migration by the activation of signalling path-
ways, cytoskeletal rearrangement, and changes in cell
surface molecules.28,29 Another important element is the
micro-vascular alterations, caused by chronic inflamma-
tion, which are observed and appear to be clinically
involved in COPD. In this regard, it has been well estab-
lished that vascular endothelial growth factor (VEGF) plays
an important role in the airway micro-vascular alterations
in mild and moderate COPD disease.30
On the other hand, different mechanisms are involved in
airway inflammations in sleep apnea patients. Indeed,
a pro-inflammatory state has been reported at both
systemic and local (upper airways) levels in these patients,
and its impact remains to be elucidated. From a generic
Figure 2 Correlation between neutrophils percentage and
PaO2 (A), ODI (B) and BMI (C) in OS, OSAS and COPD patients.
COPD and OSAS (Overlap Syndrome) 307standpoint, many studies have demonstrated that patients
with OSAS manifest high circulating levels of multiple
biomarkers connected to both systemic and local
inflammation.31,32
Several studies are available on hypoxia-mediated
inflammation in airways of OSAS patients. In this regard, an
increase in exhaled pentane and NO levels in OSAS patients
and an increase in exhaled IL-6 concentrations were
reported; indeed, in a previous study of our group, we
described a higher percentage of neutrophils in the induced
sputum of these subjects.22,23
The common hypothesis states that these phenomena
are secondary to the upper airway mechanical injury and
intermittent hypoxia, but further and more recent data
indicate that their causes and consequences might be morecomplex than was originally thought. In fact, it has been
demonstrated that apnea triggers a systemic inflammation
by inducing changes in leukocyte function in an OSAS
animal model,33 whereas sleep deprivation per se induces
spontaneous pro-inflammatory cytokine production by
human monocytes.34
Besides that, many studies suggest that obesity alone is
a direct cause of systemic inflammation35 because adipose
tissue produces different inflammatory adipokines such as
leptin, and adiponectin in particular during conditions of
hypoxia,36 while the link between obesity and airway
inflammation is not clear. Our data showed that there was
no positive correlation between BMI and the increase of
neutrophils percentage in airways, but we think that it is
not sufficient to say that pulmonary inflammation and
obesity are not linked. Thus, it remains unclear both
whether obesity per se can induce pulmonary inflammation
and what the link between this is.
Finally, our data show that only diurnal PaO2 has
a correlation with the airway percentage of neutrophils,
but this is not true for noctural hypoxiemia because no
correlation was found with TST90. We know that systemic
hypoxemia contributes to TNF-a elevation in COPD37 and
also in OSAS, and that it is independent from obesity.4 Thus,
TNF-a and related cytokine levels could lead to the
migrations of neutrophils into the airway, and this should be
particularly true in patients with the Overlap Syndrome
where, nocturnal tonic desaturations associated with
intermitted episode of hypoxia, could have additional
effects on an increased TNF-a level. However, in order to
better understand the exact mechanisms and test the
hypotheses, larger-scale studies are required.
There are several limits within this study, the most
important being the lower number of enrolled patients as
well as the difference in age between the control groups
and patients. Thus, as stated above, more studies are
needed to support our hypothesis.
In conclusion, these data show that in OSAS, COPD and
Overlap Syndrome there is an increase of neutrophils in
airway. May be neutrophils migration could be sustained by
different mechanisms in these three diseases. However,
Overlap Syndrome is the only disease in which upper and
lower airway obstruction are both present and often asso-
ciated with obesity. Indeed, it is for this reason that in this
case each phenomena can likely contribute to sustained
inflammatory status.
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